HLA-DQ2 peptide vaccine - ImmusanT

Drug Profile

HLA-DQ2 peptide vaccine - ImmusanT

Alternative Names: Coeliac disease peptide vaccine - ImmusanT; Nexvax2

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator Nexpep
  • Developer ImmusanT
  • Class Immunotherapies; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Coeliac disease

Most Recent Events

  • 27 Feb 2017 Phase-I development in Coeliac disease is ongoing in Australia and New Zealand
  • 22 Feb 2017 ImmusanT completes a phase Ib trial in Coeliac disease in Australia and New Zealand (9211861; NCT02528799)
  • 22 Feb 2017 ImmusanT plans a phase II trial for Coeliac disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top